Vol 64, No 5 (2013)
Review paper
Published online: 2013-11-01

open access

Page views 3011
Article views/downloads 3143
Get Citation

Connect on Social Media

Connect on Social Media

Reimbursement of metformin for polycystic ovary syndrome

Andrzej Milewicz
DOI: 10.5603/EP.2013.0025
Endokrynol Pol 2013;64(5):409-414.

Abstract

The latest list of reimbursed medicines includes, as a new addition, metformin for the treatment of polycystic ovary syndrome (PCOS),
which is extremely important for practicing physicians. While this paper briefly summarises the current state of knowledge on PCOS,
its main aim is to remind the reader about the effectiveness of metformin in women with PCOS in controlling glycaemia, increasing
tissue sensitivity to insulin and affecting endothelial function, vascular inflammation, lipid profile and other risk factors of atherosclerosis,
which suggests its cardioprotective effects. The paper also discusses the clinical effect of metformin relative to hyperandrogenism,
menstrual cycle disorders and ovulation induction. The paper concludes with an algorithm for the diagnosis and management of PCOS.

(Endokrynol Pol 2013; 64 (5): 409–414)